# NGM BIOPHARMACEUTICALS INC

NGM BIOPHARMACEUTICALS INC is a company headquartered in South San Francisco, CA, United States.

## Company overview

- **Legal name:** NGM BIOPHARMACEUTICALS INC
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** South San Francisco, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001426332

## About

NGM BIOPHARMACEUTICALS INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001426332, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2024-03-11, it reported annual revenue of USD 4,417,000; net income of USD -142,375,000; total assets of USD 168,868,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $4.4M (USD 4,417,000)
- **Net income:** -$142.4M (USD -142,375,000)
- **Total assets:** $168.9M (USD 168,868,000)
- **Cash and equivalents:** $55.8M (USD 55,816,000)
- **Operating cash flow:** -$132.2M (USD -132,202,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $55.3M (USD 55,333,000)
- **Net income:** -$162.7M (USD -162,667,000)
- **Total assets:** $307.4M (USD 307,402,000)
- **Cash and equivalents:** $73.5M (USD 73,456,000)
- **Operating cash flow:** -$144.4M (USD -144,439,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $77.9M (USD 77,882,000)
- **Net income:** -$120.3M (USD -120,335,000)
- **Total assets:** $402.4M (USD 402,387,000)
- **Cash and equivalents:** $151.8M (USD 151,795,000)
- **Operating cash flow:** -$73.2M (USD -73,229,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $87.4M (USD 87,368,000)
- **Net income:** -$102.5M (USD -102,487,000)
- **Total assets:** $329.0M (USD 329,043,000)
- **Cash and equivalents:** $147.0M (USD 147,017,000)
- **Operating cash flow:** -$83.5M (USD -83,496,000)

## Recent SEC filings

- Form 8-K — filed 2024-04-05 — period 2024-04-05 — 8-K
- Form 10-K/A — filed 2024-04-04 — period 2023-12-31 — 10-K/A
- Form 10-K — filed 2024-03-11 — period 2023-12-31 — 10-K
- Form 8-K — filed 2024-03-11 — period 2024-03-11 — 8-K
- Form 8-K — filed 2024-02-26 — period 2024-02-25 — 8-K
- Form 8-K — filed 2024-01-22 — period 2024-01-18 — 8-K
- Form 8-K — filed 2024-01-02 — period 2023-12-28 — 8-K
- Form 8-K — filed 2023-12-04 — period 2023-12-01 — 8-K
- Form 10-Q — filed 2023-11-02 — period 2023-09-30 — 10-Q
- Form 8-K — filed 2023-11-02 — period 2023-11-02 — 8-K
- Form 8-K — filed 2023-10-17 — period 2023-10-17 — 8-K
- Form 8-K — filed 2023-08-11 — period 2023-08-09 — 8-K

---

Updated: 2026-10-23T19:32:55Z

Canonical page: https://altss.com/profile/ngm-biopharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology